Jenny is a partner in our Antitrust, Competition and Trade group. She advises clients on all aspects of EU and UK competition law, including merger control and foreign investment, Articles 101/102 and equivalent UK legislation, digital regulation, market/sector investigations and strategic antitrust counselling.
Jenny has experience of advising clients across a wide range of industries, with a particular emphasis on the life sciences/healthcare and technology sectors. Highlights include advising on high-profile, complex merger control and foreign investment process across multiple jurisdictions, including public takeovers. In addition to representing clients before UK and EU competition authorities, Jenny has extensive experience of counselling clients on a wide range of antitrust issues, including competitor collaborations, joint ventures, all aspects of vertical relationships, pricing and contractual arrangements.
Clients appreciate Jenny’s pragmatic, commercially minded approach, and her ability to quickly gain a deep understanding of their business. Jenny is recognised by Who’s Who Legal as a future leader and by WomenAT as a Private Practice Rising Star.
Jenny is also a member of the Brussels bar and spends time working across our London and Brussels offices.
- Advising a Global Technology Company on the CMA's cloud infrastructure market investigation, Ofcom’s cloud services market study, the EU Data Act and various global matters.
- AstraZeneca on its $1.1bn acquisition of Icosavax, a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle platform.
- Roivant on the $7bn sale of its Telavant business to Roche.
- AstraZeneca on $1.2bn acquisition of Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases.
- AstraZeneca on its $2.4bn acquisition of Fusion, a clinical-stage biopharmaceutical company developing next-generation radio-conjugates.
- Novartis on the UK and EU regulatory aspects of various acquisitions, including its €2.7bn acquisition of MorphoSys.
- Zeus, a specialist provider of tubing for medical devices, on its acquisition by EQT.
- AstraZeneca on its collaboration and investment agreement with Cellectis SA
- Alexion, AstraZeneca Rare Disease, on its acquisition of LogicBio, a genomic medicine company.
- CVC on the merger control aspects of its €1.5bn investment in the Ligue de Football Professionnel's new commercial subsidiary.
- London Stock Exchange Group on its $27bn acquisition of Refinitiv, a financial information, data and analytics provider, which required review by 20 antitrust authorities worldwide, including in-depth merger reviews in the EU and US, as well as foreign investment reviews in several jurisdictions.
- Honeywell on the combination of Honeywell Quantum Solutions and Cambridge Quantum Computing and acquisition of a majority stake in the combined company.
- AstraZeneca on its $6bn global development and commercialisation agreement with Daiichi Sankyo.
- Comcast on the global merger control and public interest aspects of its £30bn public bid for Sky plc, including achieving unconditional Phase 1 clearance from the European Commission, and advising on the global merger control and public interest aspects of its $66bn bid for the global assets of 21st Century Fox. Read more about the deal in our case study.
- Berry Global on the global merger control and competition aspects of its £5.1bn public bid for RPC Group.
- AstraZeneca on its $8.5bn strategic oncology collaboration with Merck.
- Experian plc on the CMA's Phase 2 investigation into its proposed acquisition of ClearScore.
- London Stock Exchange Group on its recommended £21bn merger with Deutsche Börse.
- Betfair on its £5bn merger with Paddy Power.
- Poundland plc on the CMA's Phase 2 investigation into its acquisition of 99p Stores.
- ChemChina on the global merger control and foreign investment aspects of its $1bn acquisition of industrial machinery maker KraussMaffei Group and its $8bn public bid for Italian tyre giant Pirelli, which required clearance in over 15 jurisdictions.
